Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences, Inc.    GILD


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Covid-19 Drug Remdesivir Fully Approved by FDA

10/22/2020 | 04:24pm EST

By Joseph Walker

The U.S. Food and Drug Administration has granted a full final approval to Gilead Sciences Inc.'s remdesivir, making it the first Covid-19 treatment deemed safe and effective by the regulator, the company said Thursday.

Remdesivir has been widely used to treat hospitalized Covid-19 patients since May, when it received a provisional clearance from regulators known as an emergency-use authorization. Emergency authorizations are used to quickly get experimental drugs to patients without other treatment options in the event of biological and other threats.

Under the full-fledged approval, remdesivir is greenlighted to treat patients ages 12 years and older who require hospitalization for Covid-19. The FDA said remdesivir, which is sold under the brand-name Veklury, should be given via daily intravenous infusions for five days in most patients or 10 days among those on ventilators or life support.

It has shown modest effectiveness in clinical trials but has become the standard of care in hospitalized patients because of the dearth of other treatments.

In early October, President Trump was treated with remdesivir along with an experimental antibody treatment made by Regeneron Pharmaceuticals Inc.

Gilead had originally studied remdesivir as an Ebola treatment, but it proved less effective than other medicines treating that disease. When the new coronavirus was identified in January, the company was already working with academic researchers to study its potential in treating other coronaviruses, such as Middle East respiratory syndrome, or MERS. The company was soon helping supply clinical trials in China and eventually in the U.S.

"It is incredible to be in the position today, less than one year since the earliest case reports of the disease now known as Covid-19, of having an FDA-approved treatment in the U.S. that is available for all appropriate patients in need," Gilead Chief Executive Daniel O'Day said in a statement.

At the same time it issued a full approval, the FDA authorized remdesivir's emergency use in patients younger than 12 years. Clinical trials testing the drug in those younger patients are ongoing.

The FDA approval is based primarily on a U.S. trial of 1,062 patients that found remdesivir sped up patients' recovery time by five days compared with placebo. The study failed to show a statistically significant benefit in reducing deaths, however.

Other studies have failed to show a clinically meaningful benefit from taking remdesivir compared with standard treatment or placebo.

Analysts on average project global remdesivir sales of $2.3 billion in 2020 and $2.1 billion in 2021, according to FactSet.

"The formal FDA approval doesn't change our estimates or outlook for remdesivir given it has already been branded standard-of-care prior to formal approval," said Steven Seedhouse, a Raymond James analyst, in a note to clients.

Gilead shares rose 3.8% in after-hours trading following the approval.

(END) Dow Jones Newswires

10-22-20 1824ET

Stocks mentioned in the article
ChangeLast1st jan.
GILEAD SCIENCES, INC. 0.34% 59.66 Delayed Quote.-8.43%
RAYMOND JAMES FINANCIAL -0.09% 93.405 Delayed Quote.4.50%
REGENERON PHARMACEUTICALS 1.20% 515.33 Delayed Quote.35.38%
All news about GILEAD SCIENCES, INC.
11/25EU seeks to bypass patents to boost drugs access in crises
11/24GILEAD SCIENCES : to Present at the 3rd Annual Evercore ISI HealthCONx Conferenc..
11/23GILEAD SCIENCES : to Present at the 3rd Annual Evercore ISI HealthCONx Conferenc..
11/23Canada could approve COVID-19 vaccines early next year -regulator
11/23GILEAD SCIENCES : U.S. infectious disease group backs Gilead's remdesivir for CO..
11/21FDA Authorizes Regeneron's Covid-19 Antibody Cocktail Drug -- Update
11/20WALL STREET STOCK EXCHANGE : Stocks decline as COVID-19 cases surge
11/20NEWS HIGHLIGHTS : Top Company News of the Day
11/20Health Care Down, But Not By Much, Amid Vaccine Optimism -- Health Care Round..
11/20Post Holdings, Gilead Sciences fall; Pfizer, Hibbett rise
More news
Financials (USD)
Sales 2020 23 650 M - -
Net income 2020 34,3 M - -
Net Debt 2020 20 525 M - -
P/E ratio 2020 -4 365x
Yield 2020 4,58%
Capitalization 74 585 M 74 585 M -
EV / Sales 2020 4,02x
EV / Sales 2021 3,83x
Nbr of Employees 11 800
Free-Float 99,6%
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 73,52 $
Last Close Price 59,50 $
Spread / Highest target 76,5%
Spread / Average Target 23,6%
Spread / Lowest Target -2,52%
EPS Revisions
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
William A. Lee Executive Vice President-Research
Merdad V. Parsey Chief Medical Officer
George Pratt Shultz Director-Emeritus
Sector and Competitors
1st jan.Capitalization (M$)
WUXI APPTEC CO., LTD.56.53%37 992
BIONTECH SE209.80%25 273
GENMAB A/S55.72%24 142